Denison Mines announces $250 million convertible notes offering
DUBLIN - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported better-than-expected fourth quarter results, but its shares fell 3% in after-hours trading as investors focused on the company’s subdued revenue guidance for 2025.
The biopharmaceutical company posted adjusted earnings per share of $6.60 for Q4, surpassing analyst estimates of $5.79. Revenue came in at $1.1 billion, also beating the consensus forecast of $1.06 billion.
Jazz saw strong performance across its portfolio in the fourth quarter. Xywav sales jumped 19% YoY to $401 million, while Epidiolex revenue rose 14% to $275 million. The company’s oncology segment also showed solid growth, with Zepzelca sales increasing 6% to $78.3 million.
For the full year 2024, Jazz reported total revenue of $4.07 billion, up 6% from 2023. The company generated over $1.4 billion in cash from operations during the year.
"2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals.
However, Jazz’s 2025 revenue guidance of $4.15-$4.4 billion came in slightly below analyst expectations of $4.3 billion at the midpoint. This outlook appears to have disappointed investors, leading to the stock’s decline despite the Q4 beat.
The company expects adjusted EPS of $22.50-$24.00 for 2025, compared to the consensus estimate of $22.03.
Jazz highlighted several pipeline developments, including the recent U.S. approval and launch of Ziihera for biliary tract cancer. The company also plans to submit an application for Zepzelca in first-line small cell lung cancer in the first half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.